Scalable Synthesis and New Bond Disconnections

可扩展的合成和新的键断裂

基本信息

  • 批准号:
    10373114
  • 负责人:
  • 金额:
    $ 109.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Natural products have long held societal value as folk medicines, and even in this modern era, many FDA-approved drugs are still being derived from terpenes and alkaloids found in nature. Biomedical research has also benefited from natural products, as previously unknown mechanisms of action have been discovered while studying the unique biochemical pathways that these compounds undergo in the human body. Furthermore, endeavors in the total synthesis of these architecturally diverse compounds have continuously provided chemists with challenges, which in turn have led to the establishment of research programs in both academic and industrial environments. Ever since its inception, our laboratory has been pursuing, and has succeeded in, the total synthesis of iconic natural products in both the terpene and alkaloid families. These syntheses have identified gaps in the chemical literature, which we have subsequently addressed. The products of this research program—new synthetic strategies, unprecedented transformations and novel reagents—have in turn enabled the synthesis of even more natural products and pharmaceutically relevant motifs, thus completing a catalytic cycle of discovery. We seek to replicate this success with the current proposal: the described projects will target complex natural products to identify shortcomings in chemical methodology, while simultaneously devising methods of widespread interest, followed by the assessment of their practicality in the synthesis of complex molecules. For the next five years our laboratory will generate chemical knowledge that transcends the original objective of natural product synthesis. We will focus on efficiently synthesize complex natural products aiming for ideality. We will also develop of useful methods for synthesis and medicinal chemistry. The resulting procedures will be utilized in the construction of complex pharmaceutical motifs, which will serve to expand chemical space and accelerate discovery in drug discovery. Notably, we have already established numerous collaborations to study the biological properties of the products that will be synthesized, to validate and field-test new methods, and to commercialize reagents for widespread adoption in both academic and industrial settings. Lastly, we will focus on strategic applications and development of synthetic organic electrochemical methods, wherein the development of oxidative mediators for C-H functionalization, desaturation of carbonyls, and reductive cross-couplings are presented.
项目摘要/摘要 长期以来,天然产品作为民间药物一直具有社会价值,即使在现代, 许多FDA批准的药物仍然是从自然界中发现的萜类和生物碱中提取的。 生物医学研究也受益于天然产品,这在以前是未知的 在研究独特的生化途径时,已经发现了作用机制。 这些化合物在人体内所经历的。此外,还努力在全合成方面做出努力 这些结构多样的化合物不断地给化学家带来挑战, 这反过来又导致了学术和工业领域的研究计划的建立 环境。自成立以来,我们的实验室一直在探索,并取得了成功, 萜类和生物碱家族中标志性天然产物的全合成。这些 合成已经确定了化学文献中的空白,我们随后解决了这一问题。 这项研究计划的产品-新的综合战略,前所未有的转变 和新的试剂-反过来又使合成更多的天然产品和 与药物相关的基序,从而完成了发现的催化循环。我们寻求 将这种成功复制到当前的提案中:所描述的项目将以Complex Natural为目标 产品识别化学方法学中的缺陷,同时设计 普遍感兴趣的方法,然后评估它们在综合中的实用性 复杂的分子。在接下来的五年里,我们的实验室将产生化学知识 这超越了天然产物合成的最初目标。我们将高效地专注于 以理想为目标合成复杂的天然产物。我们还将开发有用的方法 用于合成和药物化学。由此产生的程序将用于施工 复杂的药物主题,这将有助于扩大化学空间和加速 药物发现中的发现。值得注意的是,我们已经建立了许多合作关系,以 研究将要合成的产品的生物学特性,以进行验证和现场测试 新的方法,并将试剂商业化,以便在学术和 工业背景。最后,我们将重点介绍合成材料的战略应用和发展。 有机电化学方法,其中C-H氧化介体的发展 介绍了官能化、羰基的去饱和化和还原交叉偶联。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PHIL S BARAN其他文献

PHIL S BARAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PHIL S BARAN', 18)}}的其他基金

Scalable Synthesis and New Bond Disconnections
可扩展的合成和新的键断裂
  • 批准号:
    9891858
  • 财政年份:
    2016
  • 资助金额:
    $ 109.42万
  • 项目类别:
Scalable Synthesis and New Bond Disconnections
可扩展的合成和新的键断裂
  • 批准号:
    10580740
  • 财政年份:
    2016
  • 资助金额:
    $ 109.42万
  • 项目类别:
Scalable Synthesis and New Bond Disconnections
可扩展的合成和新的键断裂
  • 批准号:
    10164654
  • 财政年份:
    2016
  • 资助金额:
    $ 109.42万
  • 项目类别:
Scalable Synthesis and New Bond Disconnections
可扩展的合成和新的键断裂
  • 批准号:
    9677411
  • 财政年份:
    2016
  • 资助金额:
    $ 109.42万
  • 项目类别:
Transcriptional silencing of latent HIV infection - a novel small molecule class
潜伏 HIV 感染的转录沉默——一类新型小分子
  • 批准号:
    8731293
  • 财政年份:
    2014
  • 资助金额:
    $ 109.42万
  • 项目类别:
Preparative Radical Chemistry for Biomedical Research
生物医学研究的制备自由基化学
  • 批准号:
    8996063
  • 财政年份:
    2013
  • 资助金额:
    $ 109.42万
  • 项目类别:
Preparative Radical Chemistry for Biomedical Research
生物医学研究的制备自由基化学
  • 批准号:
    8795737
  • 财政年份:
    2013
  • 资助金额:
    $ 109.42万
  • 项目类别:
Preparative Radical Chemistry for Biomedical Research
生物医学研究的制备自由基化学
  • 批准号:
    8485337
  • 财政年份:
    2013
  • 资助金额:
    $ 109.42万
  • 项目类别:
Synthesis of Complex Terpenes
复杂萜烯的合成
  • 批准号:
    8636031
  • 财政年份:
    2011
  • 资助金额:
    $ 109.42万
  • 项目类别:
Synthesis of Complex Terpenes
复杂萜烯的合成
  • 批准号:
    8242687
  • 财政年份:
    2011
  • 资助金额:
    $ 109.42万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 109.42万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 109.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 109.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 109.42万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 109.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 109.42万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 109.42万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 109.42万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 109.42万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 109.42万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了